Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC4005-001 · 1 trial · 1 indication
Measured as count of events
| Arm | Type | Description |
|---|---|---|
| NNC4005-0001 | EXPERIMENTAL | Participants will receive a single dose of NNC4005-0001 injected subcutaneously. Trial will include up to 6 ascending single-dose cohorts. |
| Placebo | PLACEBO_COMPARATOR | Participants in each cohort will receive placebo matched to NNC4005-0001 injected subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC4005-001 | DRUG | NNC4005-0001 will be given as a single ascending dose via subcutaneous route |
| Placebo | DRUG | Placebo matched to NNC4005-0001 will be given via subcutaneous route |
Inclusion Criteria: * Aged 18-69 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) of 27.0-40.0 kilogram per square meter (kg/m\^2) (both inclusive) at screening process. * Hepatic fat fraction greater than or equal to (≥) 8% by magnetic resonance imaging p...
NNC4005-001 is an investigational small molecule developed by Novo Nordisk A/S for fatty liver disease. It is in Phase 1 clinical development and is being studied in adults with increased body weight and liver fat. It has not been approved by any regulatory agency and remains an experimental therapy.
NNC4005-001 is being studied for fatty liver disease in adults who have increased body weight and liver fat. The research program is in Phase 1, so the drug is investigational and is not yet available as a treatment. Its use is currently limited to clinical trial participants.
NNC4005-001 is developed by Novo Nordisk A/S, which trades under the ticker NVO. The company is running the clinical program for this small molecule candidate in fatty liver disease.
NNC4005-001 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The program currently has one active trial, which is no longer recruiting participants.
NNC4005-001 is being evaluated in the Phase 1 trial NCT07214870, titled a research study of a potential new medicine for liver disease in adult participants with increased body weight and liver fat. The trial is active but not recruiting, is placebo controlled and double blind, and enrolled 29 participants in Canada.
No. The Phase 1 trial NCT07214870 for NNC4005-001 enrolls adults with fatty liver disease and increased body weight rather than healthy volunteers. Participants must be 18 years or older, and the study accepts all sexes. It is conducted in Canada and is currently active but not recruiting.